Every material Form 8-K Zoetis filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zoetis completed a private offering of $2.0 billion in 0.25% convertible senior notes due June 15, 2029, including a $250 million option that the initial purchasers exercised in full. The company estimates net proceeds of about $1,969.6 million and plans to use most of them to repurchase its common stock under its existing $6 billion repurchase program, with the remaining buybacks expected to be completed by the first quarter of 2026.
Notes total $2.0 billion principal, with a 0.25% annual interest rate payable semiannually starting June 15, 2026
Estimated net proceeds of $1,969.6 million: $186.6 million for capped call transactions, $248.0 million to buy about 2.1 million shares, and $1,535.0 million for further repurchases
Initial conversion price is about $148.20 per share, a 22.5% premium to the December 15, 2025 NYSE closing price
Notes mature June 15, 2029 and are senior unsecured obligations of Zoetis
Zoetis reported third quarter 2025 revenue of $2.4 billion, up 1% from a year earlier, and net income of $721 million, or $1.63 per diluted share, up 9%. The company revised its full year 2025 revenue guidance to $9.400 billion to $9.475 billion, citing broader macro trends and the operating environment, and kept its adjusted diluted EPS guidance at $6.30 to $6.40. The filing does not state the prior revenue guidance range, so the size of the change cannot be measured from this document.
Q3 2025 revenue was $2.4 billion, up 1% reported and up 4% on an organic operational basis.
Q3 2025 adjusted net income was $754 million, or $1.70 per diluted share, up 8% on a reported basis.
Full year 2025 revenue guidance is $9.400 billion to $9.475 billion, with organic operational growth of 5.5% to 6.5%.
Full year 2025 adjusted diluted EPS guidance is unchanged at $6.30 to $6.40; reported diluted EPS guidance is $5.90 to $6.00.
Zoetis Inc. said its Board appointed Stephanie Tilenius as a director, effective December 1, 2025, and will expand the Board from twelve to thirteen members at that time. The filing describes her background in digital health and technology, and it reports no arrangements with third parties and no reportable related party transactions. The change adds a director with digital health and AI experience and does not involve a change in financial results or guidance.
Board appointed Stephanie Tilenius on October 23, 2025; her term starts December 1, 2025.
Board size increases from twelve to thirteen members effective December 1, 2025.
She previously founded Vida Health, Inc. and served as its CEO from 2014 to 2023; she also held senior roles at Google, PayPal and eBay.
Company will enter into its standard indemnification agreement with her.
Zoetis signed a new five-year, $1.25 billion senior unsecured revolving credit agreement on August 27, 2025, which replaced its existing revolving facility. The company can request an increase in commitments to up to $1.75 billion, subject to conditions, and may prepay borrowings without penalty. The filing describes a leverage ratio covenant and other customary terms, but it does not report any new borrowings or financial results.
New $1.25 billion five-year senior unsecured revolving credit facility dated August 27, 2025, with JPMorgan Chase Bank, N.A. as administrative agent
Commitments can be increased to up to $1.75 billion, subject to certain conditions
Prior credit agreement dated December 21, 2022, was terminated on August 27, 2025; it was scheduled to expire in December 2027
Facility includes a maximum total leverage ratio covenant and voluntary prepayment without penalty or premium
Zoetis reported second-quarter 2025 revenue of $2.5 billion, up 4% on a reported basis and 8% on an organic operational basis, and net income of $718 million, or $1.61 per diluted share, up 15% and 18%. The company raised its full-year 2025 revenue guidance to $9.450 billion to $9.600 billion and its adjusted diluted EPS guidance to $6.30 to $6.40, which is the main change for shareholders.
Q2 2025 revenue was $2.5 billion, with U.S. segment revenue of $1.4 billion and International segment revenue of $1.1 billion.
Q2 2025 net income was $718 million, or $1.61 per diluted share; adjusted net income was $783 million, or $1.76 per diluted share.
Full-year 2025 revenue guidance rose to $9.450 to $9.600 billion from $9.425 to $9.575 billion.
Full-year 2025 adjusted diluted EPS guidance rose to $6.30 to $6.40 from $6.20 to $6.30; reported diluted EPS guidance is $5.90 to $6.00.
At its annual meeting on May 21, 2025, Zoetis shareholders elected twelve directors, including Dr. Mark Stetter, who joins the board effective that date. Robert Scully retired from the board effective May 21, 2025, under the company's director retirement policy. Shareholders also approved the advisory executive compensation vote, ratified KPMG LLP as auditor, and did not approve a shareholder proposal on a special shareholder meeting.
Robert Scully retired from the board effective May 21, 2025, under the company's director retirement policy.
Dr. Mark Stetter was elected to the board; he will serve on the Quality and Innovation Committee.
Non-binding say-on-pay vote passed with 334,181,202 votes for and 35,190,564 against.
Shareholder proposal on a special shareholder meeting failed with 50,420,440 votes for and 320,662,986 against.
Zoetis reported first-quarter 2025 revenue of $2.2 billion, up 1% on a reported basis and 9% on an organic operational basis, and net income of $631 million, or $1.41 per diluted share. The company raised its full-year 2025 revenue and adjusted diluted EPS guidance, but lowered its organic operational growth outlook for adjusted net income to 5% to 7% due to enacted tariffs.
Q1 2025 net income was $631 million, or $1.41 per diluted share, up 5% and 8% on a reported basis; adjusted diluted EPS was $1.48.
Full-year 2025 revenue guidance raised to $9.425 billion to $9.575 billion from $9.225 billion to $9.375 billion, reflecting foreign exchange.
Adjusted diluted EPS guidance raised to $6.20 to $6.30 from $6.00 to $6.10, reflecting foreign exchange and enacted tariffs.
Organic operational growth guidance for adjusted net income cut to 5% to 7% from 6% to 8%, reflecting enacted tariffs.
Zoetis reported fourth quarter and full year 2024 results and issued full year 2025 guidance. Fourth quarter revenue was $2.3 billion, up 5%, and full year revenue was $9.3 billion, up 8%, with reported diluted EPS of $5.47 for the year. For 2025, the company expects revenue of $9.225 billion to $9.375 billion and reported diluted EPS of $5.70 to $5.80, or adjusted diluted EPS of $6.00 to $6.10.
Fourth quarter 2024 net income was $581 million, or $1.29 per diluted share, up 11% and 13% on a reported basis.
Full year 2024 revenue was $9.3 billion, up 8%, and net income was $2.5 billion, or $5.47 per diluted share.
2025 guidance: revenue of $9.225 billion to $9.375 billion; reported diluted EPS of $5.70 to $5.80; adjusted diluted EPS of $6.00 to $6.10.
The medicated feed additive portfolio divestiture was completed on October 31, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zoetis filing is on SEC EDGAR ↗. 8-K briefs of other companies →